OMNIPOD® WILL BE COMING HOME IN EUROPE



Insulet Corporation has announced its decision to establish direct operations for its Omnipod® System in Europe, effective July 1, 2018

Hear from Shacey Petrovic, Insulet’s President and Chief Operating Officer:

"We are excited to establish a direct local presence in Europe. This will allow us to be closer to the diabetes community, deepen our understanding of European customer needs and further incorporate these into our innovation pipeline."

"This is a natural step forward for Insulet, as we work to expand the reach of Omnipod® to benefit more people living with insulin-dependent diabetes around the world. We have a strong leadership team in Europe with the skills and experience to support the Omnipod® System based on our already established U.S. and Canadian markets. We look forward to building on our existing relationships and developing new ones within the European diabetes community."

WHAT DOES THIS MEAN FOR ME?

  • +What is happening?
    Insulet has announced that it will assume the distribution, sales, marketing, training and support for the Omnipod® System across Europe once its agreement with Ypsomed AG ends on June 30, 2018. Insulet is committed to working closely with Ypsomed to ensure continuity of care for Omnipod® System users.
  • +Is the Omnipod® System the same product as the mylife OmniPod®?
    Yes. The Omnipod® System is the same product as mylife OmniPod® and has always been manufactured by Insulet.
  • +How will this transition affect the supply of my Omnipod® products?
    This transition will not affect the supply of your Omnipod® products. Insulet is committed to working closely with Ypsomed to ensure continuity of care for Omnipod® System users.
  • +Does my point of contact change?
    No. Ypsomed will continue to operate as your point of contact during the transition period. You should continue to contact Ypsomed for any product enquiries or customer service needs.
  • +Whom should I speak to about any product issues?
    Ypsomed will continue to operate as your point of contact during the transition period. Please continue to contact Ypsomed on the following numbers for any product enquiries or customer service needs:
    • Austria: (+43) 00800 55 00 00 00
    • France: (+33) 0800 883056
    • Germany: (+49) 0800 9776633
    • Italy: (+39) 0332 189 0607
    • Netherlands: (+31) 0800 9776633
    • Sweden: (+46) 020 612 200
    • Switzerland: (+41) 0800 44 11 44
    • UK: (+44) 0344 856 7820
    • General number for Ypsomed AG: (+41) 34 424 41 41

  • +Does this change how I order mylife OmniPod® products?
    No. Ypsomed continues to be responsible for all mylife OmniPod® product orders. Users will be given advance notification of any changes to the ordering process to ensure continuity of care.
  • +How do I stay up-to-date with future developments for the Omnipod® System in Europe?
    Insulet is committed to ensuring that all Omnipod® System users, healthcare professionals and payers are aware of the transition plan with plenty of notice so there is no disruption to services. Please check the Omnipod® System website (www.myomnipod.com/europe) for the latest information and updates.

ABOUT

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Insulet seeks to expand the use of insulin pump therapy with its Omnipod® Insulin Management System among people with insulin-dependent diabetes. The Omnipod® System is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business partners with global pharmaceutical and biotechnology companies to adapt the Omnipod® technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.

© 2017 Insulet Corporation. Omnipod and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.


mylife is a trademark owned or licensed to the Ypsomed Group and used with permission.


18648-5A-AW R1 07/17